The Board of Directors approved the draft separate financial statements and the consolidated financial statements as at 31 December 2023.
Pro forma 2023 with Argentea and Evolucare:
Revenues € 477.8 M; EBITDA € 96.9 M (margin 20.3%); Net profit € 9.1 M
CONSOLIDATED FINANCIAL STATEMENT*
- Revenues: € 433 M (FY22: € 347 M, +25%)
- EBITDA: € 80 M (FY22: € 49 M, +64%)
- EBITDA margin: 18.4% (FY22: 14.0%)
- Net profit: € 6.8 M
- Net financial debt: € 365 M (FY22: € 143 M), of which net debt to financial institutions of € 274 M (FY22: € 65 M), gross of divestment of Argentea (€ 99 M)
*Following the divestment of Argentea S.r.l., which took place on March 20, 2024, the consolidated income statements for 2022 and 2023 present the results of Argentea in a line item outside of EBITDA (IFRS5 principle).
Fausto Manzana, CEO of the Gpi Group:
“2023 was another particularly significant year for Gpi, characterised by a significant transformational drive that saw us grow in size, in completeness of offer and in market presence, both in Italy and internationally. A year in which we achieved ahead of schedule what we had set out to do, namely, consolidate our leadership in the field of the digital transformation of healthcare with growth abroad that places us among the leading players in Europe.
The investments made with recent acquisitions and the sale of Argentea support the transformation of our Group into a multinational entity. Our goal is ambitious but clear: to become a leading European company in healthcare system innovation through our state-of-the-art software solutions and technologies.
I am thinking of solutions for virtualisation of care and artificial intelligence systems that can improve the quality of diagnosis, treatment and the health of people. Our commitment to innovate, generating value for the entire ecosystem in which we operate, is relevant and constant.
All in all it was a very satisfying 2023, the best possible basis for continuing our development path towards sustainable healthcare”.
